Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders
David A. Williams
Harvard Medical School, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Address correspondence to: David A. Williams, Leland Fikes Chair of Pediatrics, Harvard Medical School, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, 300 Longwood Ave. Karp 08125.3, Boston, Massachusetts 02115, USA. Phone: 617.919.2697; Email: DAWilliams@childrens.harvard.edu.
Find articles by Williams, D. in: JCI | PubMed | Google Scholar
First published March 4, 2019 - More info
J Clin Invest. 2019;129(4):1519–1521. https://doi.org/10.1172/JCI127582.
© 2019 American Society for Clinical Investigation
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases. In a study published in this issue of the JCI, Stivala et al. explored the key observation that JAK inhibition successfully suppresses MAPK activation in MPN cell lines and primary MPN cells in vitro, and the finding that it failed to completely and effectively suppress MAPK activation in vivo in two mouse models. The authors went on to show that dual inhibition of JAK and the MAP kinase pathway provided enhanced therapeutic efficacy in the in vivo models of MPN.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)